United Healthcare Stock Is Down 50% From Its Peak — And Analysts Say Now Is the Time to Pay Attention

In a glass office tower in Minnetonka, Minnesota, UnitedHealth Group has subtly grown to become one of the most significant businesses in America by handling health insurance at scale, a practice that causes more resentment than nearly any other business activity. In 2025, the company reported revenue of $448 billion. It has about 390,000 employees. More healthcare claims are processed by it than by any other private organization in the nation. Its stock is currently trading at about $304 as of April 2026, which is more than 50% less than the peak it reached just two years prior. One of the most noticeable discrepancies in the large-cap world at the moment is the difference between this company’s operational value and what the market currently believes it is worth.

For UNH, the last two years have been extremely challenging in ways that go beyond normal market cycles. The percentage of insurance premiums paid out as claims, or the company’s medical loss ratio, increased from 85.5% in 2024 to 88.9% in 2025. That figure is the primary indicator of a health insurer’s profitability, and when it fluctuates, everything else does too. Earnings reached about $19 billion, a 41% year-over-year decline. One of the company’s subsidiaries, Change Healthcare, was the target of a cyberattack that caused weeks of disruption to claims processing and resulted in expenses that took months to fully account for.

The program that had been the company’s most dependable growth engine saw margins squeezed when Medicare Advantage reimbursement rates fell short of expectations. Then, in late 2024, the company’s CEO was assassinated, which not only caused grief within the company but also sparked more intense and intimate public criticism of health insurance practices than the sector had seen in years.

Driven by the announcement that the Centers for Medicare & Medicaid Services finalized a 2.48% increase in Medicare Advantage reimbursement rates for 2027, last week’s 8% single-day rally was genuine and significant. According to Bernstein’s analysis, what had been predicted as a 4% drag on 2027 earnings now looked more like 1.4% earnings growth. This was a significant improvement over the flat rates that the initial proposal had suggested. The analyst maintained a buy rating while increasing the price target to $411. HSBC changed its status from Sell to Hold. The analyst community’s signal is generally positive; 22 out of 31 analysts who cover UNH have Buy ratings, and the consensus 12-month price target suggests an increase of about 17% from current levels.

Michael Ha of Baird is the lone defender, maintaining his Underperform rating while making a compelling case that the structural pressures on value-based care have not subsided and that the Medicare rate increase might only provide short-term respite. It’s not a position on the periphery. The medical loss ratio issue is a utilization issue as well as a reimbursement issue, which means that more healthcare services are being used than actuarial models predicted. While some of that may be the result of longer-term behavioral changes, some of it is post-pandemic catch-up. It is genuinely unclear how much of the increased utilization will continue into 2026 and 2027, and the answer is crucial for determining whether the current P/E of 23 appears cheap or warily prudent.

The near-term earnings drama overshadows an intriguing structural case for UNH. It would be more accurate to characterize the company as a vertically integrated healthcare organization, with Optum acting as its core, rather than just a health insurer. Optum offers health services technology and analytics, manages pharmacy benefits, and owns a network of clinics.

Optum offers a layer of earnings stability that a pure-play insurer could not depend on when the insurance side of the business is under margin pressure. More than any underlying decline in the Optum businesses, the company’s revenue trajectory—$448 billion in 2025, with the forecast for 2026 suggesting a potential contraction that would be the first in over 30 years—reflects the challenges in the insurance sector. When considering valuation, that distinction is important.

It’s difficult to ignore the fact that, for the first time in decades, the political climate surrounding health insurance has truly turned hostile. Following the events of late 2024, discussions about insurance practices, claim denials, and network adequacy continued in regulatory discussions, congressional hearings, and the public’s consciousness.

It’s unclear if this results in significant legislative changes or if it just acts as a general cultural pressure on the industry. The Q1 2026 earnings report will be the next significant checkpoint to determine whether the medical loss ratio is truly improving or if the worst is still to come. It is evident that UnitedHealth’s management is navigating something more complex than a typical industry cycle.